• S Fukudo, A Nakajima, Y Fujiyama, M Kosako, A Nakagawa, H Akiho, Y Nakashima, J M Johnston, and H Miwa.
• Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
• Neurogastroenterol. Motil. 2018 May 1; 30 (5): e13275.

BackgroundClinical testing to determine a suitable dose of linaclotide for Japanese patients with irritable bowel syndrome with constipation (IBS-C) was needed.MethodsThis was a randomized, double-blind, placebo-controlled, dose-finding trial. Japanese patients with IBS-C diagnosed using Rome III criteria (n = 559, men/women: 49/510) were randomly assigned to 1 of 4 linaclotide doses (0.0625, 0.125, 0.25, or 0.5 mg) or placebo for the 12-week treatment period. The primary endpoint was responder rate of global assessment of relief of IBS symptoms during 12 weeks. The secondary endpoints included responder rates of complete spontaneous bowel movement (CSBM), SBM and abdominal pain/discomfort relief and others.Key ResultsThe primary endpoint was 23.2%, 36.2%, 38.7%, 34.8%, and 38.3% in placebo (n = 112), 0.0625 (n = 116), 0.125 (n = 111), 0.25 (n = 112), and 0.5 (n = 107) mg of linaclotide groups with the difference from the placebo group in each linaclotide group (13.0%, 15.5%, 11.6%, 15.1%, P > .05). Monthly responder rate of global assessment of relief of IBS symptoms at month 3 (48.6%), responder rate of CSBM during 12 weeks (45.8%), and responder rate of abdominal pain/discomfort relief during 12 weeks (32.7%) in the 0.5 mg were significantly higher than those in placebo group (29.5%, P < .01; 25.9%, P < .01; and 18.8%, P < .05 respectively). The most frequent adverse event in the linaclotide groups was diarrhea.Conclusions & InferencesThis study suggests that a linaclotide dose of 0.5 mg may be appropriate in Japanese patients with IBS-C.© 2017 The Authors. Neurogastroenterology & Motility Published by John Wiley & Sons Ltd.

29 keywords...

hide…